An analysis of recently launched meds holds some clues to successful—and not so successful—rollouts.

Amgen’s cholesterol-fighter Repatha rolled back atherosclerosis in a new clinical trial, but the results might not be enough to give the PCSK9 drug an…

Teva is trying to clean the slate on its history of allegedly paying bribes in foreign countries and has put aside more than half a billion dollars to cover…

If Novartis does snap up Amneal to beef up its own Sandoz unit, the deal will say as much about the state of the under-pressure generics industry as it does…

While industry closely tracks developments on the Department of Justice price-fixing investigation into a host of generics companies, one influential analyst…

Word is Pfizer is considering selling or spinning off its consumer health operations and that it could bring in $14 billion or more.

Seeking to overcome a wave of public and governmental attention to its EpiPen, Mylan is working to finalize its $465 million settlement with the federal…

Months into a bruising EpiPen pricing scandal, congressional scrutiny on Mylan continues to heat up. Top members of the Senate Judiciary Committee have called…

Corporate